Although the sample size of this study was small, as B-ALL patients with low WBC were not eligible for the FACS protocol we implemented, we believe that it provided pure BM and PB CD10 + /CD19 + pre-B lymphoblast samples without other contaminating white cells or non-leukemic cells. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.